skip to page content

Homology Medicines Receives Award for Revolutionary New Therapeutic or Platform Startup from New England Venture Capital Association

BEDFORD, Mass., May 10, 2018 – Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it received a 2018 NEVYs award from the New England Venture Capital Association in the category of Revolutionary New Therapeutic or Platform Startup. 

As New England’s premier awards program for the technology, healthcare and life science communities, the NEVYs honor the best and brightest in the region’s venture ecosystem. Homology’s award was determined by the NEVYs Healthcare & Life Sciences Academy, which comprises venture capital executives.

About Homology Medicines, Inc.
Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases, and intellectual property covering its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines. For more information, please visit